LLY

766.38

+2.78%↑

JNJ

177.06

-0.18%↓

ABBV

216.94

+1.09%↑

UNH

342.77

-1.67%↓

AZN

77.82

+0.31%↑

LLY

766.38

+2.78%↑

JNJ

177.06

-0.18%↓

ABBV

216.94

+1.09%↑

UNH

342.77

-1.67%↓

AZN

77.82

+0.31%↑

LLY

766.38

+2.78%↑

JNJ

177.06

-0.18%↓

ABBV

216.94

+1.09%↑

UNH

342.77

-1.67%↓

AZN

77.82

+0.31%↑

LLY

766.38

+2.78%↑

JNJ

177.06

-0.18%↓

ABBV

216.94

+1.09%↑

UNH

342.77

-1.67%↓

AZN

77.82

+0.31%↑

LLY

766.38

+2.78%↑

JNJ

177.06

-0.18%↓

ABBV

216.94

+1.09%↑

UNH

342.77

-1.67%↓

AZN

77.82

+0.31%↑

Search

CytoSorbents Corp

Open

SectorHealthcare

0.88 -2.22

Overview

Share price change

24h

Current

Min

0.89

Max

0.91

Key metrics

By Trading Economics

Income

3.4M

1.9M

Sales

890K

9.6M

Profit margin

20.245

Employees

149

EBITDA

-3.1M

-3.6M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+6.38% upside

Dividends

By Dow Jones

Next Earnings

6 lis 2025

Market Stats

By TradingEconomics

Market Cap

4.6M

62M

Previous open

3.1

Previous close

0.88

News Sentiment

By Acuity

46%

54%

177 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

CytoSorbents Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 wrz 2025, 22:39 UTC

Acquisitions, Mergers, Takeovers

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 wrz 2025, 16:43 UTC

Major Market Movers

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 wrz 2025, 16:42 UTC

Major Market Movers

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 wrz 2025, 16:35 UTC

Major Market Movers

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 wrz 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 wrz 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 wrz 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 wrz 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 wrz 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

CSL Expects Commercial Launch in 2029

15 wrz 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 wrz 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 wrz 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 wrz 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 wrz 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 wrz 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 wrz 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 wrz 2025, 21:14 UTC

Acquisitions, Mergers, Takeovers

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 wrz 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 wrz 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 wrz 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 wrz 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 wrz 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 wrz 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15 wrz 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 wrz 2025, 17:50 UTC

Acquisitions, Mergers, Takeovers

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 wrz 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 wrz 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 wrz 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 wrz 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15 wrz 2025, 16:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

Peer Comparison

Price change

CytoSorbents Corp Forecast

Price Target

By TipRanks

6.38% upside

12 Months Forecast

Average 1 USD  6.38%

High 1 USD

Low 1 USD

Based on 2 Wall Street analysts offering 12 month price targets forCytoSorbents Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

2 ratings

0

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

0.705 / 0.771Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

177 / 371 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
help-icon Live chat